biotech · Acute Myeloid Leukemia (AML) · Ovarian Cancer · STRO
SUTRO BIOPHARMA
SUTRO BIOPHARMA, INC.
SUTRO BIOPHARMA is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker STRO. Primary therapeutic focus areas include Acute Myeloid Leukemia (AML), Ovarian Cancer, Lung Cancer,
South San Francisco, USA HQ
2003 Founded
212 Employees
Public company Type
STRO · NYSE Ticker
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2003
- Employees
- 212
- Programs
- 10
- Drugs
- 21
- Patents
- 34
Luveltamab tazevibulin
Phase 2 · small molecule · Acute Myeloid Leukemia (AML)
Luveltamab tazevibulin for Acute Myeloid Leukemia (AML) is a Phase 2 program (small_molecule) at SUTRO BIOPHARMA, INC. with 1 ClinicalTrials.gov record(s).
Internal code REFRαME P1
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- SUTRO BIOPHARMA, INC.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Acute Myeloid Leukemia (AML)
- Status
- terminated
- Trials
- 1